SYNTHESIS OF MODIFIED PYRIDINE AND BIPYRIDINE SUBSTITUTED COUMARINS AS POTENT ANTIMICROBIAL AGENTS


Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations

Introduction: EGFR exon 20 insertion mutations account for 10% of all EGFR mutations and are mostly insensitive to approved EGFR tyrosine kinase inhibitors (EGFR TKIs).Novel EGFR TKIs have been developed or repurposed for these mutants.A limited number of preclinical studies have detailed these EGFR TKIs.We sought to use commercially available mobo

read more